Show stories from Brazil Latin America

News from aidsmap

  • US backs down on generics for S Africa

    Michael Carter | 12 November 2001

    In the face of international and domestic pressure, the United States has conceded that South Africa and other developing countries can break international patent agreements to obtain cheaper versions of ...

  • T-20 expanded access study announced

    Anna Poppa | 07 November 2001

    Roche have announced plans for widening access to their experimental fusion inhibitor, T-20 (pentafuside), a new type of anti-HIV treatment. A worldwide open-label safety study, codenamed T-20 305, is ...

  • Repairing facial fat loss

    Keith Alcorn | 25 October 2001

    Studies on two treatments for repairing facial fat loss were presented at this week’s Third International Workshop on Adverse Drug reactions and Lipodystrophy in HIV Infection in Athens. Polymethyl methylcrylate (PMMA) isyes">  a ...

  • 25,000 volunteers to be sought for vaccine trials

    Julian Meldrum | 09 September 2001

    Two large US-funded vaccine efficacy trials are now in late planning stages and likely to begin in 2002. Both would test canarypox vaccines made by Aventis Pasteur as “primers” followed ...

  • Pharma companies agree further price cuts as generics challenge

    Michael Carter | 06 September 2001

    Two major drug companies have agreed price cuts which will see cheaper HIV treatments available in Brazil and the Caribbean. Under pressure from the Brazilian government, Swiss based Hoffman-La Roche, ...

  • Nigeria plans large scale access to generic drugs

    Keith Alcorn | 31 July 2001

    The Nigerian government will start providing antiretroviral treatment to 15,000 individuals already diagnosed with AIDS in September after an agreement with the Indian antiretroviral manufacturer CIPLA for provision of a ...

  • Drug access table: June 2001 update

    Keith Alcorn | 20 June 2001

    This table updates an edition published in April to include new data on prices and discounts offered by several Indian manufacturers of generic antiretrovirals, with the brand names of their ...

  • How cheaply can HIV drugs be made?

    Keith Alcorn | 24 April 2001

    Two important investigations on the cost of anti-HIV drugs were published today by the New York Times, highlighting some interesting facts about the true production costs of antiretroviral drugs, and ...

Editors’ picks from other sources

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.